Cargando…

Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

BACKGROUND: More accurate risk assessments are needed to improve prostate cancer management. OBJECTIVE: To identify blood-based protein biomarkers that provided prognostic information for risk stratification. DESIGN, SETTING, AND PARTICIPANTS: Mass spectrometry was used to identify biomarker candida...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guldvik, Ingrid J., Zuber, Verena, Braadland, Peder R., Grytli, Helene H., Ramberg, Håkon, Lilleby, Wolfgang, Thiede, Bernd, Zucknick, Manuela, Saatcioglu, Fahri, Gislefoss, Randi, Kvåle, Rune, George, Anne, Grönberg, Henrik, Wiklund, Fredrik, Neal, David E., Gnanapragasam, Vincent J., Taskén, Kristin A., Mills, Ian G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317831/ https://www.ncbi.nlm.nih.gov/pubmed/34337468 http://dx.doi.org/10.1016/j.euros.2020.08.007

Ejemplares similares

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

β-Adrenergic Receptor Signaling in Prostate Cancer
por: Braadland, Peder Rustøen, et al.
Publicado: (2015)

Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
por: Ramberg, Håkon, et al.
Publicado: (2021)

Novel concepts for risk stratification in prostate cancer
por: Patel, Keval M, et al.
Publicado: (2016)

Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
por: Barrett, Tristan, et al.
Publicado: (2022)

Population‐based study of long‐term functional outcomes after prostate cancer treatment
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
por: Gongora, Magdalena, et al.
Publicado: (2022)

Low β(2)-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
por: Braadland, Peder Rustøen, et al.
Publicado: (2015)

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
por: Koitsalu, Marie, et al.
Publicado: (2021)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
por: Waldén, Mauritz, et al.
Publicado: (2022)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
por: Nordström, Tobias, et al.
Publicado: (2021)

Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer
por: Axén, Elin, et al.
Publicado: (2021)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO
por: Nyberg, Martin, et al.
Publicado: (2020)

Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
por: Braadland, Peder R, et al.
Publicado: (2018)

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
por: Braadland, Peder R, et al.
Publicado: (2017)

Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
por: Remmers, Sebastiaan, et al.
Publicado: (2022)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method
por: Thurtle, D, et al.
Publicado: (2018)

Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists
por: Dovey, Zachary, et al.
Publicado: (2020)

Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence
por: Sivanesan, Shivanthe, et al.
Publicado: (2022)

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
por: Ramberg, Håkon, et al.
Publicado: (2011)

TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells
por: Eide, Turid, et al.
Publicado: (2013)

Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment
por: Da Rosa, M.R., et al.
Publicado: (2011)

Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT)
por: Murray, Louise J., et al.
Publicado: (2014)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting
por: Donaldson, Ian A., et al.
Publicado: (2015)

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy
por: Jensen, Lindsay, et al.
Publicado: (2017)

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017)

Transurethral bipolar plasmakinetic vapo-enucleation of the prostate: Is it safe for patients on chronic oral anticoagulants and/or platelet aggregation inhibitors?
por: El-Shaer, Waleed, et al.
Publicado: (2017)

Day care bipolar transurethral resection vs photoselective vaporisation under sedoanalgesia: A prospective, randomised study of the management of benign prostatic hyperplasia
por: Sood, Rajeev, et al.
Publicado: (2017)

Can androgen-deprivation therapy obviate the need of channel transurethral resection of the prostate in advanced prostate cancer with urinary retention? A prospective study
por: Sood, Rajeev, et al.
Publicado: (2017)

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital
por: Kan, Carolyn K., et al.
Publicado: (2017)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
por: Wang, Wei Gang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_89i2jkpsret5jdlolu5no3osa7